The objective of the study is the documentation of the safety and effectiveness profile of the CE-labeled immunoadsorbers GLOBAFFIN® and LIGASORB® in clinical routine according to their intended use.~The primary objective for the IgG adsorber GLOBAFFIN® and LIGASORB® is the estimation of the mean relative reduction in total IgG from pre- to post-treatment per treatment session.
Documentation of the safety and effectiveness profile of the CE-labelled immunoadsorbers GLOBAFFIN® and LIGASORB® in clinical routine according to their intended use.